Serum Soluble ST2. A Potential Novel Mediator in Left Ventricular and Infarct Remodeling After Acute Myocardial Infarction

Journal of the American College of Cardiology

Volumn 55, Issue 3, 2010, Pages 243-250

  Weir, Robin A P ^a   Miller, Ashley M ^b   Murphy, Grace E J ^b   Clements, Suzanne ^a   Steedman, Tracey ^a   Connell, John M C ^c   McInnes, Iain B ^b   Dargie, Henry J ^a   McMurray, John J V ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

aldosterone; cardiac magnetic resonance; myocardial infarction; remodeling; ST2

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FIBRINOLYTIC AGENT; FUROSEMIDE; GADOLINIUM PENTETATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR; NORADRENALIN; SOLUBLE INTERLEUKIN 1 RECEPTOR FAMILY MEMBER ST2; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD CLOT LYSIS; CARDIAC PATIENT; CONTRAST ENHANCEMENT; FEMALE; HEART INDEX; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC DYSFUNCTION;

AGED; ALDOSTERONE ANTAGONISTS; BIOLOGICAL MARKERS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SPIRONOLACTONE; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 73549106841     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.08.047     Document Type: Article

References (26)

1. Tominaga S., Kuroiwa K., Tago K., Iwahana H., Yanagisawa K., and Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 264 (1999) 14-18
2. Weinberg E.O., Shimpo M., De Keulenaer G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106 (2002) 2961-2966
3. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
4. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., and Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117 (2007) 1538-1549
5. Januzzi Jr. J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department study. J Am Coll Cardiol 50 (2007) 607-613
6. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109 (2004) 2186-2190
7. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008) 1936-1944
8. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., and Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107 (2003) 721-726
9. Rehman S.U., Mueller T., and Januzzi Jr. J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52 (2008) 1458-1465
10. Weir R.A., Mark P.B., Petrie C.J., et al. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?. Am Heart J 157 (2009) 1088-1096
11. Cerqueira M.D., Weissman N.J., Dilsizian V., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002) 539-542
12. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453
13. Lund G.K., Stork A., Saeed M., et al. Acute myocardial infarction: evaluation with first-pass enhancement and delayed enhancement MR imaging compared with 201Tl SPECT imaging. Radiology 232 (2004) 49-57
14. Zhang Y., Yip G.W., Chan A.K., et al. Left ventricular systolic dyssynchrony is a predictor of cardiac remodeling after myocardial infarction. Am Heart J 156 (2008) 1124-1132
15. Bellenger N.G., Davies L.C., Francis J.M., Coats A.J., and Pennell D.J. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2 (2000) 271-278
16. Wu K.C., Zerhouni E.A., Judd R.M., et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97 (1998) 765-772
17. Ito H., Maruyama A., Iwakura K., et al. Clinical implications of the "no reflow" phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93 (1996) 223-228
18. Schroeder A.P., Houlind K., Pedersen E.M., Nielsen T.T., and Egeblad H. Serial magnetic resonance imaging of global and regional left ventricular remodeling during 1 year after acute myocardial infarction. Cardiology 96 (2001) 106-114
19. Brilla C.G., Matsubara L.S., and Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25 (1993) 563-575
20. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 (2001) 1689-1697
21. Delyani J.A., Robinson E.L., and Rudolph A.E. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 281 (2001) H647-H654
22. Fraccarollo D., Galuppo P., Hildemann S., Christ M., Ertl G., and Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 42 (2003) 1666-1673
23. Pitt B., Zannad F., Remme W.J., et al. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 4341 (1999) 709-717
24. Pitt B., Remme W.J., Zannad F., et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
25. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14 (2008) 732-738
26. Kakkar R., and Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 (2008) 827-840